DC Circ. Rejects Esai's Petition Over Seizure Med Delay

Law360, Chicago (October 25, 2013, 2:56 PM EDT) -- The D.C. Circuit on Tuesday shot down a bid from a U.S. unit of Japan’s Eisai Co. Ltd. to force the U.S. Drug Enforcement Administration to speed up the process for scheduling its epilepsy drug Fycompa as a controlled substance, saying the company had not shown the need for such drastic action.

In a brief order, the three-judge panel denied the drugmaker’s petition for a writ of mandamus. However, the decision came after the DEA agreed to take the initial step in the scheduling process by...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re: Eisai Inc.


Case Number

13-1243

Court

Appellate - DC Circuit

Nature of Suit

Date Filed

August 19, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.